RAD51 testing shows promise in personalized early breast cancer treatment
Published in Clinical Cancer Research, results of a VHIO-led study underscore the potential of the RAD51 biomarker in ...
Hosted on MSN1d
Biomarker May Flag Humira Responders in Hidradenitis Suppurativa
Serum level of inflammatory marker C-reactive protein (CRP) predicted response to adalimumab (Humira) treatment for patients ...
Healio4h
Direct switch from TNFi to tofacitinib shows ‘acceptable’ safety in psoriatic arthritis
For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no ...
clinicalpainadvisor.com4d
Higher Adalimumab Trough Levels Improve Outcomes in Rheumatoid Arthritis
Adalimumab trough levels of 4.0 mg/L or higher among patients with RA were linked to greater treatment response and ...
EurekAlert!1d
The promise of RAD51 testing in tailoring treatment strategies in early breast cancer
In this post hoc analysis, we evaluated if the RAD51 test could identify patients with different responses to neoadjuvant ...
aTyr Pharma: Interesting Drug, Difficult Target Market
Tyr Pharma's stock surged on positive data for pulmonary sarcoidosis treatment, but cash balance risk keeps investors ...
Too Old to Operate1d
Exploring Digital Health’s Role in Managing MSK Conditions in Obesity
The following is a summary of “Evaluating Digital Rehabilitation Outcomes in Chronic Musculoskeletal Conditions Across Non-Obesity, Obesity, and Severe Obesity,” published in the January 2025 issue of ...